Randall B. Sunberg

Partner

Randall B. Sunberg is a partner in Morgan Lewis's Business and Finance Practice, vice chair of the firm's Life Sciences Interdisciplinary Group, and co-chair of the firm's Life Sciences Transactions Practice.

Mr. Sunberg's clients range from early-stage biotechnology start-ups to global pharmaceutical companies, as well as specialty pharma, medical device, and other technology companies. His clients also include private equity, venture capital, and investment banking firms focused on the life sciences industry. He advises these clients on a variety of mission-critical transactions, including negotiation and structuring of acquisitions, divestitures, joint ventures, corporate partnering, licensing and other complex collaborations, and the equity investments and other securities matters that often accompany such transactions. Related matters include the technical contractual arrangements for drug discovery, development, manufacturing and supply, marketing, and outsourcing in the life sciences industry. He also advises boards of directors and significant shareholders on disclosure issues, corporate communications policies and fiduciary duty matters.

Mr. Sunberg has spoken on the subjects of mergers and acquisitions, strategic alliances, and licensing and collaboration transactions in the United States at BIO Annual Meetings and LES Annual Meetings, in Canada at BIOMedex, and in China at BIOForum, as well as at other life-sciences-related conferences and as guest lecturer at the Rutgers Business School MBA Biotechnology Commercialization Concentration.

Mr. Sunberg is admitted to practice in New Jersey, Pennsylvania, New York, and Missouri.

Representative Transactions:

• Shire in its up to $325 million development and commercialization collaboration with Alba Therapeutics for gastrointestinal permeability inhibitor AT-1001
• Adolor in its up to $265 million development and commercialization collaboration with Pfizer for delta opioid agonists
• Acura Pharmaceuticals in its development and commercialization collaboration with King Pharmaceuticals for opioid analgesic products
• Shire in its up to $440 million genetic disorders development and commercialization collaboration with Amicus Therapeutics
• NPS Pharmaceuticals in its licensing collaboration with Nycomed for Gattex
• Cardiokine in its up to $220 million development and commercialization collaboration with Biogen Idec for lixivaptan, a selective V2 vasopressin receptor agonist
• Shire in its up to $825 million development and commercialization collaboration with Renovo for Juvista (human TGFß3)
• Merck in its divestiture of several marketed products to Iroko Pharmaceuticals
• Lundbeck in its acquisition of Saegis Pharmaceuticals
• Ambrilia Biopharma in its up to $232 million worldwide licensing agreement with Merck relating to its HIV/AIDS protease inhibitor program
• Cytogen in the sale of its 50% joint venture interest in PSMA Development Company LLC to Progenics
• Schering-Plough in its global collaboration with Novartis to develop and commercialize a once-daily inhaled fixed-dose combination therapy for asthma and COPD
• Pharmasset in its development and commercialization collaboration with Bukwang Pharmaceuticals of Korea for the treatment of chronic hepatitis B virus
• Biovail Pharmaceuticals in its more than $100 million product divestiture, strategic collaboration and research and development alliance with Kos Pharmaceuticals in the area of cardiovascular disease
• Shire in its up to $500 million collaboration with New River Pharmaceuticals for the development and commercialization of a late-stage ADHD compound
• Schering-Plough in its acquisition of Bayer AG's primary care pharmaceutical product business in the United States and related strategic alliances on oncology products and on Zetia® in Japan
• Paul Royalty Fund in its revenue monetization and equity investment in Verus Pharmaceuticals
• Sanofi-Aventis in the restructuring of its Actonel® collaboration with Procter & Gamble
• Adolor in its co-promotion agreement with GlaxoSmithKline for Arixtra®
• Sanofi-Aventis in the divestiture of Campto® to Pfizer
• Cytogen in the conjugated antibody development and commercialization collaboration between PSMA Development Company LLC, Cytogen's joint venture with Progenics, and Seattle Genetics
• Sanofi-Aventis in its up to $115 million royalty monetization transaction with Paul Royalty Fund relating to sales of Lunesta® by Sepracor
• Pharmasset in its $300 million collaboration with Roche to develop and commercialize nucleoside polymerase inhibitors for the treatment of chronic hepatitis C virus infections
• Sanofi-Aventis in its up to $485 million collaboration with Regeneron to develop and commercialize VEGF-Trap products, and related equity investment
• Quintiles in its co-development and co-promotion collaboration with Eli Lilly for Cymbalta®
• Cephalon in its $444 million stock-for-stock acquisition of Anesta
• Sanofi-Aventis in its collaboration with ImmunoGen to discover, develop and commercialize novel antibody-based oncology products
• Adolor in its worldwide development and commercialization collaboration for Entereg® with GlaxoSmithKline
• Arena Pharmaceuticals in its drug discovery collaboration with Merck
• Sanofi-Aventis in the outsourcing of certain clinical and regulatory functions to Quintiles
• Sanofi-Aventis in its inhaled insulin strategic alliance with Pfizer and related collaboration and licensing arrangements with Nektar Therapeutics